An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay-Reference-Cited by-同舟云学术

An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay

Published:2023-01 Issue:1 Volume:41 Page:109-118
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Torales Julio,Cuenca-Torres Osmar,Barrios Laurentino,Armoa-Garcia Luis,Estigarribia Gladys,Sanabria Gabriela,Lin Meei-Yun,Antonio Estrada Josue,Estephan Lila,Cheng Hao-Yuan,Chen Charles,Janssen Robert,Lien Chia-En

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference31 articles.

1. Our world in data. Statistics and research coronavirus pandemic (COVID-19) [cited 2022 April 20].

2. SARS-CoV-2 variants, spike mutations and immune escape;Harvey;Nat Rev Microbiol,2021

3. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry;Peacock;BioRxiv,2022

4. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization;Planas;bioRxiv,2021

5. Antibody evasion properties of SARS-CoV-2 omicron sublineages;Iketani;bioRxiv,2022

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutaneous adverse reactions associated with COVID-19 vaccines: Current evidence and potential immune mechanisms;Clinical Immunology;2024-06

2. The use of proteins and peptides-based therapy in managing and preventing pathogenic viruses;International Journal of Biological Macromolecules;2024-06

3. Global Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread;Current Protein & Peptide Science;2024-05

4. CHO cells for virus-like particle and subunit vaccine manufacturing;Vaccine;2024-04

5. Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan;Emerging Infectious Diseases;2024-03